Drug Profile
Estradiol-transdermal - Takeda
Alternative Names: LyrelleLatest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Sekisui
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Menopausal syndrome
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 30 Jan 2001 Suspended-clinical for Menopausal syndrome in World (Transdermal)